LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 1-9

  Spillmann, Frank ^a   Van Linthout, Sophie ^a   Miteva, Kapka ^a   Lorenz, Mario ^a,b   Stangl, Verena ^a,b   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Endothelial dysfunction; LXR agonist; Nitric oxide; TNF

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ARGININOSUCCINATE SYNTHASE; CASPASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MARKER; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RETINOID X RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR RING; VASODILATATION;

ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOS; HUMAN UMBILICAL VEIN CELLS; HUVEC; LIVER X RECEPTOR; LXR; LXR AGONIST; NAD(P)H OXIDASE; NITRIC OXIDE; NO; NOX; O(2)•; REACTIVE OXYGEN SPECIES; RETINOID X RECEPTOR; ROS; RXR; SUPEROXIDE; TNF; TNF-Α; TUMOR NECROSIS FACTOR;

ANIMALS; ANTIOXIDANTS; AORTA; BENZOATES; BENZYLAMINES; CASPASE 3; CASPASE 7; CHOLESTEROL; ENDOTHELIUM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROCARBONS, FLUORINATED; MALE; NADPH OXIDASE; NITRIC OXIDE; ORPHAN NUCLEAR RECEPTORS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891600238     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.10.001     Document Type: Article

References (38)

1. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
2. Gao X., Xu X., Belmadani S., et al. TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 2007, 27:1269-1275.
3. Goodwin B.L., Solomonson L.P., Eichler D.C. Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. JBiol Chem 2004, 279:18353-18360.
4. Riad A., Westermann D., Van Linthout S., et al. Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia 2008, 51:2325-2332.
5. Yan G., You B., Chen S.P., Liao J.K., Sun J. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 2008, 103:591-597.
6. Goodwin B.L., Pendleton L.C., Levy M.M., Solomonson L.P., Eichler D.C. Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007, 293:H1115-H1121.
7. Kataoka H., Murakami R., Numaguchi Y., Okumura K., Murohara T. Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells. Eur J Pharmacol 2010, 636:36-41.
8. Gao X., Zhang H., Belmadani S., et al. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol 2008, 295:H2242-H2249.
9. Pritchard K.A., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995, 77:510-518.
10. Katz S.D., Rao R., Berman J.W., et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994, 90:12-16.
11. Im S.S., Osborne T.F. Liver X receptors in atherosclerosis and inflammation. Circ Res 2011, 108:996-1001.
12. Miao B., Zondlo S., Gibbs S., et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. JLipid Res 2004, 45:1410-1417.
13. Van Linthout S., Spillmann F., Lorenz M., et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009, 53:682-687.
14. Van Linthout S., Spillmann F., Graiani G., et al. Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. JMol Med (Berl) 2011, 89:151-160.
15. Van Linthout S., Spillmann F., Riad A., et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008, 117:1563-1573.
16. Blaschke F., Takata Y., Caglayan E., et al. Anuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ Res 2006, 99:e88-99.
17. Imayama I., Ichiki T., Patton D., et al. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 2008, 51:1631-1636.
18. Lei P., Baysa A., Nebb H.I., et al. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury. Basic Res Cardiol 2013, 108:323.
19. Tontonoz P., Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003, 17:985-993.
20. Chen J., Zhao L., Sun D., et al. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice. Inflamm Res 2012, 61:1299-1307.
21. Stangl V., Lorenz M., Meiners S., et al. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J 2004, 18:272-279.
22. Cardellini M., Menghini R., Martelli E., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009, 58:2396-2401.
23. Hsu J.J., Lu J., Huang M.S., et al. T0901317, an LXR agonist, augments PKA-induced vascular cell calcification. FEBS Lett 2009, 583:1344-1348.
24. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994, 74:1141-1148.
25. Chandra S., Romero M.J., Shatanawi A., Alkilany A.M., Caldwell R.B., Caldwell R.W. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol 2012, 165:506-519.
26. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9:213-219.
27. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
28. Li Y., Bolten C., Bhat B.G., et al. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol Endocrinol 2002, 16:506-514.
29. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. JClin Invest 1997, 100:2153-2157.
30. Ryoo S., Lemmon C.A., Soucy K.G., et al. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 2006, 99:951-960.
31. Shen L.J., Beloussow K., Shen W.C. Accessibility of endothelial and inducible nitric oxide synthase to the intracellular citrulline-arginine regeneration pathway. Biochem Pharmacol 2005, 69:97-104.
32. Marathe C., Bradley M.N., Hong C., et al. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. JBiol Chem 2006, 281:32197-32206.
33. Valledor A.F., Hsu L.C., Ogawa S., Sawka-Verhelle D., Karin M., Glass C.K. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci U S A 2004, 101:17813-17818.
34. Chalupsky K., Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 2005, 102:9056-9061.
35. Li H., Meininger C.J., Hawker J.R., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001, 280:E75-E82.
36. Chicoine L.G., Paffett M.L., Young T.L., Nelin L.D. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004, 287:L60-L68.
37. Kim J.H., Bugaj L.J., Oh Y.J., et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. JAppl Physiol 2009, 107:1249-1257.
38. Oak J.H., Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56:118-126.